This Article Abstract Full Text (PDF) All Versions of this Article: 26/2/250    most recent 01.ATV.0000199268.27395.4fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perlstein, T. S. Articles by Lee, R. T. Search for Related Content PubMed PubMed Citation Articles by Perlstein, T. S. Articles by Lee, R. T.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:250.)
© 2006 American Heart Association, Inc.

Brief Reviews

Smoking, Metalloproteinases, and Vascular Disease

Todd S. Perlstein; Richard T. Lee

From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Mass.

Correspondence to Richard T. Lee, Cardiovascular Research Laboratories, Partners Research Facility, 65 Landsdowne St., Room 279, Cambridge, MA 02139. E-mail rlee{at}rics.bwh.harvard.edu

	Abstract

Top Abstract Introduction Epidemiology of Smoking... Smoking-Related Vascular... Matrix Metalloproteinases Matrix Metalloproteinases and... Smoking, Matrix... Epidemiology of Smoking... Smoking May Activate Vascular... Smoking and Regulation of... Conclusion References

 
Smoking causes up to 11% of total global cardiovascular deaths. Smoking has numerous effects that may promote atherosclerosis through vascular inflammation and oxidative stress, but the pathogenesis of smoking-related cardiovascular disease remains incompletely understood. The matrix metalloproteinases, a family of endopeptidases that can degrade extracellular matrix components in both physiological and pathophysiological states, play an important role in smoking-associated chronic obstructive pulmonary disease, the second leading cause of smoking attributable mortality. Emerging evidence indicates that the matrix metalloproteinases may also contribute to smoking-related vascular disease. Here we discuss the potential relationship between smoking, matrix metalloproteinases, and acceleration of vascular disease.

The matrix metalloproteinases are emerging as strong candidate mediators of smoking-associated vascular disease. Smoking-induced inflammation and oxidative stress may increase metalloproteinase transcription, increase pro-enzyme activation, and limit endogenous inhibition of metalloproteinase activity. The relationship between smoking, metalloproteinases, and vascular disease is discussed in this brief review.

Key Words: vascular disease • smoking • metalloproteinases

	Introduction

Top Abstract Introduction Epidemiology of Smoking... Smoking-Related Vascular... Matrix Metalloproteinases Matrix Metalloproteinases and... Smoking, Matrix... Epidemiology of Smoking... Smoking May Activate Vascular... Smoking and Regulation of... Conclusion References

 
In the year 2000, smoking caused an estimated 1.69 million cardiovascular deaths in the world, 11% of total global cardiovascular deaths.¹ Vasomotor dysfunction, alterations in thrombosis/fibrinolysis, and modification of lipids may mediate smoking-related vascular disease, with a central role of vascular inflammation and oxidative stress.² The pathogenesis of smoking-related cardiovascular disease remains incompletely understood. The matrix metalloproteinases, a family of endopeptidases best known for degrading extracellular matrix components in both physiological and pathophysiological states, play an important role in smoking-associated chronic obstructive pulmonary disease, the second leading cause of smoking attributable mortality.^1,3,4 Recent observations suggest that the matrix metalloproteinases may also play an important role in smoking-related vascular disease.

See cover

	Epidemiology of Smoking-Associated Vascular Disease

Top Abstract Introduction Epidemiology of Smoking... Smoking-Related Vascular... Matrix Metalloproteinases Matrix Metalloproteinases and... Smoking, Matrix... Epidemiology of Smoking... Smoking May Activate Vascular... Smoking and Regulation of... Conclusion References

 
There are an estimated 1 billion smokers in the world.⁵ Cigarette smoking independently increases the risk for coronary atherosclerotic disease, cerebrovascular disease, and peripheral vascular disease.⁶ In a recent multinational case-control study of first myocardial infarction, smoking contributed 36% of the population attributable risk, and the risk of myocardial infarction increased linearly with increasing number of cigarettes smoked.⁷ The relationship between cigarette smoking and risk for stroke is also strong, with an estimated 30% of strokes attributable to smoking in a large prospective cohort study.⁸ The association of smoking with aneurysmal subarachnoid hemorrhage appears particularly strong.^9,10 In a population study of 126 196 subjects, the excess prevalence associated with smoking accounted for 75% of all abdominal aortic aneurysms >4.0 cm.¹¹ The excess prevalence associated with smoking accounted for 76% of the risk for claudication in a case-control study.¹² In a systematic review including 17 studies, smoking increased the risk of symptomatic peripheral arterial disease by 2.6-fold.¹³ The association of smoking with peripheral atherosclerotic disease appears to be stronger than that with coronary atherosclerotic disease or atherosclerotic cerebral vascular disease.⁶ In an analysis of 10 studies including >3 million subjects, the association of smoking with aortic aneurysmal disease was 2.5-times greater than that with coronary disease and 3.5-times greater than that with cerebral vascular disease.¹⁴ It is important to note that the association between cigarette smoke exposure and cardiovascular disease extends to passive smoke exposure, with second-hand smoke increasing the risk for death from ischemic heart disease by one-quarter among nonsmokers.¹⁵

	Smoking-Related Vascular Inflammation and Oxidative Stress

Top Abstract Introduction Epidemiology of Smoking... Smoking-Related Vascular... Matrix Metalloproteinases Matrix Metalloproteinases and... Smoking, Matrix... Epidemiology of Smoking... Smoking May Activate Vascular... Smoking and Regulation of... Conclusion References

 
Inflammation and arterial wall oxidative stress are central in the pathogenesis of atherosclerosis.^16–18 The ability of cigarette smoke to induce vascular inflammation and oxidative stress appears fundamental to the broad effects of smoking on vascular pathophysiology.² Smokers have higher circulating leukocyte counts and increased circulating markers of inflammation including C-reactive protein, interleukin (IL)-6, soluble intercellular adhesion molecule type 1, E-selectin, and P-selectin^19–21. Urinary excretion of 8-epi-prostaglandin (PG) F2 alpha, a stable product of lipid peroxidation in vivo, is increased in smokers and significantly lessened by vitamin C therapy.²² Cigarette smoke extract markedly increases endothelial superoxide production by NADPH oxidase.²³ Tobacco smoke condensate increases endothelial cell xanthine oxidase transcription and activity.²⁴ Hamsters exposed to cigarette smoke have increased xanthine oxidase activity that is ameliorated by coadministration of superoxide dismutase, suggesting a key role for smoke-induced superoxide.²⁵ Human endothelial cells exposed to sera from smokers have decreased nitric oxide availability despite increased nitric oxide synthase expression, with scavenging of nitric oxide by increased reactive oxygen species generation.^26,27 Smoking-associated endothelial dysfunction can be ameliorated by 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitor therapy independently of changes in lipid levels,²⁸ by supplementation with tetrahydrobiopterin,²⁶ and by xanthine oxidase inhibition with allopurinol.²⁹ Monocytes isolated from smokers demonstrate increased adherence to endothelial cells, which is corrected by vitamin C therapy.³⁰ The ability of sera collected from smokers to increase monocyte adherence to endothelial cells is ameliorated by coincubation with L-arginine.³¹ Cigarette smokers have increased autoantibody titers to oxidized low-density lipoprotein (LDL),³² and cigarette smoke extract causes oxidative modification of plasma LDL, an effect ameliorated by vitamin C.³³ The activation of platelets by sera from smokers can be inhibited in vitro by either catalase or reduced glutathione plus peroxidase.³⁴ As discussed, smoking-associated inflammation and oxidative stress may also be responsible for activation of the matrix metalloproteinases.

	Matrix Metalloproteinases

Top Abstract Introduction Epidemiology of Smoking... Smoking-Related Vascular... Matrix Metalloproteinases Matrix Metalloproteinases and... Smoking, Matrix... Epidemiology of Smoking... Smoking May Activate Vascular... Smoking and Regulation of... Conclusion References

 
The biochemistry of the matrix metalloproteinases has recently been reviewed.³⁵ The matrix metalloproteinases are a family of Zn²⁺-dependent and Ca²⁺-dependent endopeptidases that are best known for the resorption of extracellular matrix components in both normal physiological processes and pathological states. The matrix metalloproteinases can be classified into 6 main groups according to structural similarities and substrate affinities: (1) the collagenases; (2) the gelatinases; (3) the stromelysins; (4) the membrane-type matrix metalloproteinases; (5) the matrilysins; and (6) a heterogenous subgroup. Here we focus on the proteolytic effects of the matrix metalloproteinases; however, it is important to recognize that matrix metalloproteinases act on a broad range of substrates including tumor necrosis factor (TNF) alpha, growth factors and their receptors, plasminogen and its activators, and endothelin.³⁶ Thus, the matrix metalloproteinases should not simply be considered mediators of matrix degradation, despite this historic context. Similarly, the extracellular matrix is not simply an inert scaffold but plays a dynamic role in cellular functions including cell adhesion, migration, apoptosis, growth factors binding, and lipoprotein binding.³⁷

	Matrix Metalloproteinases and Vascular Pathophysiology: Focus on Vascular Remodeling and Plaque Instability

Top Abstract Introduction Epidemiology of Smoking... Smoking-Related Vascular... Matrix Metalloproteinases Matrix Metalloproteinases and... Smoking, Matrix... Epidemiology of Smoking... Smoking May Activate Vascular... Smoking and Regulation of... Conclusion References

 
Vascular remodeling, which can be defined as any enduring change in the size and/or composition of an adult blood vessel,³⁶ depends on degradation and reorganization of the extracellular matrix, and the participation of the matrix metalloproteinases is essential. Matrix metalloproteinases may disrupt and remodel extracellular matrix barriers allowing vascular smooth muscle cell (VSMC) migration, a key factor in arterial remodeling.³⁸ In addition, extracellular matrix regulates VSMC behavior by sequestering signaling molecules and by acting as contextual ligands for cellular adhesion receptors.³⁹ Monomer collagen stimulates while polymerized collagen inhibits VSMC proliferation via integrin signaling.⁴⁰ Matrix metalloproteinase activity is correlated with VSMC migration and proliferation after vascular injury,^41–43 and inhibition of matrix metalloproteinase activity suppresses VSMC proliferation.^41,44,45 Furthermore, matrix metalloproteinase expression is associated with remodeling of the vascular adventitia.^42,46 Characteristics of unstable plaques susceptible to rupture include a large lipid core, a thin fibrous cap,⁴⁷ and intraplaque hemorrhage.⁴⁸ Matrix metalloproteinases are expressed within atherosclerotic plaques,⁴⁹ particularly at the shoulder regions,⁵⁰ where increased stresses and matrix degradation may combine to rupture the fibrous cap.⁵¹ Matrix metalloproteinases may also contribute atherosclerotic plaque rupture by stimulating neovascularization via generation of angiogenic peptides.^52–54

	Smoking, Matrix Metalloproteinases, and Emphysema

Top Abstract Introduction Epidemiology of Smoking... Smoking-Related Vascular... Matrix Metalloproteinases Matrix Metalloproteinases and... Smoking, Matrix... Epidemiology of Smoking... Smoking May Activate Vascular... Smoking and Regulation of... Conclusion References

 
The well-described role of matrix metalloproteinases in the pathogenesis of smoking-related chronic obstructive pulmonary disease⁵⁵ serves as a paradigm for considering the potential role of matrix metalloproteinases in smoking-related cardiovascular disease. Cigarette smoke stimulates inflammatory cell recruitment into the lung parenchyma, leading to release of elastolytic proteases that destroy lung extracellular matrix and result in air space enlargement and emphysema.⁵⁵ The matrix metalloproteinases mediate cigarette smoke-induced inflammatory cell recruitment into the lung.^56,57 Matrix metalloproteinases may also participate in cigarette smoke-induced pulmonary vascular remodeling.^58,59 An interesting potential link between the role of matrix metalloproteinases in smoking-induced emphysema and in smoking-induced vascular disease is cadmium. Cadmium, inhaled in cigarette smoke, induces lung proteolysis.⁶⁰ MMP-2 and MMP-9 are increased in a rat model of cadmium-induced emphysema and colocalize with lung parenchyma destruction.⁶¹ Cadmium content of the infrarenal aorta increases in direct proportion to the number of pack-years of cigarettes smoked.⁶² In the NHANES cohort, cadmium exposure partially mediated the effect of smoking on peripheral arterial disease.⁶³ The relationship between cadmium exposure and matrix metalloproteinase activity in the vasculature is unexplored.

	Epidemiology of Smoking-Associated Vascular Disease Suggests a Role of Matrix Metalloproteinases

Top Abstract Introduction Epidemiology of Smoking... Smoking-Related Vascular... Matrix Metalloproteinases Matrix Metalloproteinases and... Smoking, Matrix... Epidemiology of Smoking... Smoking May Activate Vascular... Smoking and Regulation of... Conclusion References

 
The epidemiology of smoking-related cardiovascular disease suggests that matrix metalloproteinases and matrix degradation may play an important pathophysiological role. Excessive extracellular matrix breakdown is a major determinant of aortic expansion and aneurysm formation.⁶⁴ The association of smoking with aneurysmal subarachnoid hemorrhage may also point to matrix metalloproteinases, as MMP-9 was markedly increased in intracranial aneurysms.⁶⁵ Epidemiological data also implicate smoking in plaque instability. Cigarette smoking predicts premature coronary disease in men and women, hastening the presentation of unstable coronary syndromes by 1 decade.⁶⁶ Among patients with coronary artery disease, cigarette smoking accelerates coronary progression and new lesion formation as assessed by serial quantitative coronary arteriography.⁶⁷ Much of the association of cigarette smoking with acute coronary syndromes appears to be driven by the association of cigarette smoking with coronary thrombosis.⁶⁸ Cigarette smoking predicts a presentation of acute myocardial infarction versus unstable angina.^69–71 Among men with coronary disease who died suddenly, smoking was equally prevalent among those with vulnerable plaque rupture and with plaque erosion,⁶⁸ whereas in women who died of sudden coronary death, smoking appeared strongly associated with plaque erosion.⁷² Cigarette smoking may therefore be associated with fibrous plaque erosion more than with atheromatous plaque rupture.

	Smoking May Activate Vascular Sources of Matrix Metalloproteinases

Top Abstract Introduction Epidemiology of Smoking... Smoking-Related Vascular... Matrix Metalloproteinases Matrix Metalloproteinases and... Smoking, Matrix... Epidemiology of Smoking... Smoking May Activate Vascular... Smoking and Regulation of... Conclusion References

 
Activated macrophages, mast cells, T lymphocytes, endothelial cells, and VSMCs are the principal sources of matrix metalloproteinases in the vasculature.⁷³ Cigarette smoke, by increasing vascular inflammation and vascular reactive oxygen species, has the potential to increase matrix metalloproteinase expression by each of these cell types.

Leukocytes
Mast cells participate actively in the inflammatory process of atherosclerotic plaques and perhaps specifically in plaque rupture.⁷⁴ Mast cell chymase and tryptase activate matrix metalloproteinases types 1 and 3, and activated mast cells also secrete matrix metalloproteinases types 1 and 9.⁷⁵ Mast cells are activated by oxidized LDL⁷⁶ and reactive oxygen species.⁷⁷ T lymphocytes in atherosclerotic plaques also express matrix metalloproteinases.⁵⁰ T lymphocytes are activated by oxidized LDL,⁷⁸ inflammatory cytokines,⁷⁹ and interaction with adhesion molecules.⁸⁰ The uptake of oxidized LDL induces activation of macrophages, leading to the release of matrix metalloproteinases.⁸¹ Monocyte adherence to endothelial cells increases MMP-9 activity.⁸²

VSMCs
VSMCs stimulated with IL-1 and tumor necrosis factor (TNF)- synthesize gelatinases, interstitial collagenase, and stromelysin.⁸³ Cigarette smoking is associated with increased circulating levels of TNF and IL-1ß as well as increased monocyte expression of IL-1ß.⁸⁴ Nicotine increases PDGF expression from platelets.⁸⁵ Nicotine and cotinine directly stimulate VSMC collagenase, stromelysin, and gelatinase expression.⁸⁶

Endothelial Cells
TNF- and IL-1 induce matrix metalloproteinase expression by endothelial cells.⁸⁷ Coculture of vascular endothelial cells with monocytes increases matrix metalloproteinase expression,⁸⁸ and cigarette smoke increases monocyte adhesion to endothelial cells.^31,89 Ligation of CD40 on endothelial cells is associated with increased metalloproteinase expression,⁹⁰ and cigarette smokers have upregulation of the CD40/CD40L dyad.⁹¹ These data suggest that cigarette smoke associated inflammation and oxidative stress may induce matrix metalloproteinase expression by key cellular sources of these enzymes.

	Smoking and Regulation of Matrix Metalloproteinase Activity

Top Abstract Introduction Epidemiology of Smoking... Smoking-Related Vascular... Matrix Metalloproteinases Matrix Metalloproteinases and... Smoking, Matrix... Epidemiology of Smoking... Smoking May Activate Vascular... Smoking and Regulation of... Conclusion References

 
Activity of matrix metalloproteinases is regulated at the levels of gene transcription, proenzyme activation, and endogenous inhibitors of matrix metalloproteinases (Figure).³ Cigarette smoke-induced inflammation and oxidative stress have the potential to induce and inhibit matrix metalloproteinase activity at multiple levels. Reactive oxygen species⁹² and decreased nitric oxide activity⁹³ induce matrix metalloproteinase transcription. Cigarette smoke may increase matrix metalloproteinase expression via activation of inflammatory transcription factors. The expression of the AP-1 transcription factor complex is positively associated with matrix metalloproteinase expression,^94,95 and cigarette smoke is associated with increased expression of AP-1.^96,97 Secretion of MMP-1 and MMP-3 from macrophages stimulated in vitro or in vivo depends on the activation of NF-B,⁹⁸ and NF-B is required for cytokine upregulation of MMP-1, MMP-3, and MMP-9 in VSMCs.⁹⁹ Cigarette smoke itself is associated with activation of NF-B.¹⁰⁰ Plasmin activates matrix metalloproteinases, and smoking is associated with increased plasminogen activator levels.¹⁰¹ Reactive oxygen species activate latent proforms of matrix metalloproteinases,¹⁰² and antioxidant species decrease matrix metalloproteinase expression and activation.⁹² Nitric oxide inhibits matrix metalloproteinase activation.¹⁰³ IL-1ß decreases tissue inhibitor of metalloproteinase expression.¹⁰⁴ Reactive oxygen species induce tissue inhibitor of metalloproteinase activity.¹⁰⁵ Smoking is associated with increased TGF-ß levels,¹⁰⁶ by which smoking may inhibit metalloproteinase gene expression³ and induce tissue inhibitor of metalloproteinase expression.¹⁰⁵ The effect of cigarette smoking on matrix metalloproteinase activity is therefore complex and would be determined by the balance of matrix metalloproteinase and tissue inhibitor of metalloproteinase activities.

View larger version (41K): [in this window] [in a new window]   Potential means by which cigarette smoke may increase matrix metalloproteinase (MMP) activity. Cigarette smoke-induced inflammation and oxidative stress has the potential to induce metalloproteinase gene expression, induce pro-enzyme activation, and inhibit endogenous inhibitors of metalloproteinase activity. Reactive oxygen species induce gene expression, activate latent pro-enzymes, and inhibit tissue inhibitors of metalloproteinases (TIMPs). Scavenging of nitric oxide can increase metalloproteinase gene expression and pro-enzyme activation. Inflammatory cytokines induce metalloproteinase gene expression. Not shown, increased TGF-ß levels associated with smoking may inhibit metalloproteinase gene expression and induce TIMPs. The effect of cigarette smoking on MMP activity is therefore complex and would be determined by the balance of MMP and TIMP activities.

Studies directly examining the effect of smoking on matrix metalloproteinase activity are sparse. Exposure of endothelial cells to cigarette smoke condensate induces expression of MMP-1, MMP-8, and MMP-9.¹⁰⁷ Carotid endarterectomy specimens from cigarette smokers have higher MMP-12 and lower TIMP-1 expression than those from nonsmokers, and this is associated with decreased elastin content.¹⁰⁸ Variation in the stromeolysin-1 gene and smoking status demonstrated synergy in conferring risk for myocardial infarction.¹⁰⁹

	Conclusion

Top Abstract Introduction Epidemiology of Smoking... Smoking-Related Vascular... Matrix Metalloproteinases Matrix Metalloproteinases and... Smoking, Matrix... Epidemiology of Smoking... Smoking May Activate Vascular... Smoking and Regulation of... Conclusion References

 
Whereas an extensive body of literature indirectly implicates matrix metalloproteinases in the pathogenesis of smoking-associated vascular disease, few studies directly addressing this question have been performed. Investigations into smoking-related lung disease provide a paradigm by which to explore the role of matrix metalloproteinases in smoking-related vascular disease. For example, these studies raise the question of cadmium in cigarette smoke as a potential mediator of disease. Another interesting question that remains to be answered is whether the stronger association of smoking with peripheral than coronary atherosclerotic disease might be explained by spatial differences in MMP expression or activation. More clearly defining the role of matrix metalloproteinases in smoking related-vascular disease may provide new opportunities for the treatment of vascular disease among smokers.

Received September 20, 2005; accepted November 28, 2005.

	References

Top Abstract Introduction Epidemiology of Smoking... Smoking-Related Vascular... Matrix Metalloproteinases Matrix Metalloproteinases and... Smoking, Matrix... Epidemiology of Smoking... Smoking May Activate Vascular... Smoking and Regulation of... Conclusion References

 

1. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003; 362: 847–852.[CrossRef][Medline] [Order article via Infotrieve]
2. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004; 43: 1731–1737.[Abstract/Free Full Text]
3. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995; 77: 863–868.[Free Full Text]
4. Shapiro SD, Ingenito EP. The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years. Am J Respir Cell Mol Biol. 2005; 32: 367–372.[Free Full Text]
5. Peto RL, A.D. Future worldwide health effects of current smoking patterns. In: Koop CE, Pearson CE, Schwarz MR, eds. Critical Issues in Global Health. San Francisco, CA: Jossey-Bass; 2001.
6. O’Donnell CJ, Kannel WB. Epidemiology of Atherosclerotic Vascular Disease. In: Lanzer PT, Topel EJ, eds. Panvascular Medicine. Berlin: Springer-Verlag; 2003.
7. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937–952.[CrossRef][Medline] [Order article via Infotrieve]
8. Yamagishi K, Iso H, Kitamura A, Sankai T, Tanigawa T, Naito Y, Sato S, Imano H, Ohira T, Shimamoto T. Smoking raises the risk of total and ischemic strokes in hypertensive men. Hypertens Res. 2003; 26: 209–217.[CrossRef][Medline] [Order article via Infotrieve]
9. Isaksen J, Egge A, Waterloo K, Romner B, Ingebrigtsen T. Risk factors for aneurysmal subarachnoid haemorrhage: the Tromso study. J Neurol Neurosurg Psychiatry. 2002; 73: 185–187.[Abstract/Free Full Text]
10. Ruigrok YM, Buskens E, Rinkel GJ. Attributable risk of common and rare determinants of subarachnoid hemorrhage. Stroke. 2001; 32: 1173–1175.[Abstract/Free Full Text]
11. Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS, Barone GW, Bandyk D, Moneta GL, Makhoul RG. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med. 2000; 160: 1425–1430.[Abstract/Free Full Text]
12. Cole CW, Hill GB, Farzad E, Bouchard A, Moher D, Rody K, Shea B Cigarette smoking and peripheral arterial occlusive disease. Surgery. 1993; 114: 753–757.[Medline] [Order article via Infotrieve]
13. Willigendael EM, Teijink JA, Bartelink ML, Kuiken BW, Boiten J, Moll FL, Buller HR, Prins MH. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg. 2004; 40: 1158–1165.[CrossRef][Medline] [Order article via Infotrieve]
14. Lederle FA, Nelson DB, Joseph AM. Smokers’ relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. J Vasc Surg. 2003; 38: 329–334.[CrossRef][Medline] [Order article via Infotrieve]
15. Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ. 1997; 315: 973–980.[Abstract/Free Full Text]
16. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999; 138: S419–S420.[CrossRef][Medline] [Order article via Infotrieve]
17. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135–1143.[Abstract/Free Full Text]
18. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995; 25: 155–161.[Abstract/Free Full Text]
19. Petitti DB, Kipp H. The leukocyte count: associations with intensity of smoking and persistence of effect after quitting. Am J Epidemiol. 1986; 123: 89–95.[Abstract/Free Full Text]
20. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997; 17: 2167–2176.[Abstract/Free Full Text]
21. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol. 2002; 89: 1117–1119.[CrossRef][Medline] [Order article via Infotrieve]
22. Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 1996; 94: 19–25.[Abstract/Free Full Text]
23. Jaimes EA, DeMaster EG, Tian RX, Raij L. Stable compounds of cigarette smoke induce endothelial superoxide anion production via NADPH oxidase activation. Arterioscler Thromb Vasc Biol. 2004; 24: 1031–1036.[Abstract/Free Full Text]
24. Kayyali US, Budhiraja R, Pennella CM, Cooray S, Lanzillo JJ, Chalkley R, Hassoun PM. Upregulation of xanthine oxidase by tobacco smoke condensate in pulmonary endothelial cells. Toxicol Appl Pharmacol. 2003; 188: 59–68.[CrossRef][Medline] [Order article via Infotrieve]
25. Lehr HA, Kress E, Menger MD, Friedl HP, Hubner C, Arfors KE, Messmer K. Cigarette smoke elicits leukocyte adhesion to endothelium in hamsters: inhibition by CuZn-SOD. Free Radic Biol Med. 1993; 14: 573–581.[CrossRef][Medline] [Order article via Infotrieve]
26. Barua RS, Ambrose JA, Eales-Reynolds LJ, DeVoe MC, Zervas JG, Saha DC. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation. 2001; 104: 1905–1910.[Abstract/Free Full Text]
27. Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation. 2003; 107: 2342–2347.[Abstract/Free Full Text]
28. Beckman JA, Liao JK, Hurley S, Garrett LA, Chui D, Mitra D, Creager MA. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res. 2004; 95: 217–223.[Abstract/Free Full Text]
29. Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation. 2003; 107: 416–421.[Abstract/Free Full Text]
30. Weber C, Erl W, Weber K, Weber PC. Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Circulation. 1996; 93: 1488–1492.[Abstract/Free Full Text]
31. Adams MR, Jessup W, Celermajer DS. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J Am Coll Cardiol. 1997; 29: 491–497.[Abstract]
32. Heitzer T, Yla-Herttuala S, Luoma J, Kurz S, Munzel T, Just H, Olschewski M, Drexler H. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation. 1996; 93: 1346–1353.[Abstract/Free Full Text]
33. Frei B, Forte TM, Ames BN, Cross CE. Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid. Biochem J. 1991; 277 (Pt 1): 133–138.
34. Blache D. Involvement of hydrogen and lipid peroxides in acute tobacco smoking-induced platelet hyperactivity. Am J Physiol. 1995; 268: H679–685.
35. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92: 827–839.[Abstract/Free Full Text]
36. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002; 90: 251–262.[Abstract/Free Full Text]
37. Libby P, Lee RT. Matrix matters. Circulation. 2000; 102: 1874–1876.[Free Full Text]
38. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Develop Biol. 2001; 17: 463–516.[CrossRef][Medline] [Order article via Infotrieve]
39. Streuli C. Extracellular matrix remodelling and cellular differentiation. Curr Opin Cell Biol. 1999; 11: 634–640.[CrossRef][Medline] [Order article via Infotrieve]
40. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell. 1996; 87: 1069–1078.[CrossRef][Medline] [Order article via Infotrieve]
41. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994; 75: 539–545.[Abstract/Free Full Text]
42. Zempo N, Kenagy RD, Au YP, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg. 1994; 20: 209–217.[Medline] [Order article via Infotrieve]
43. Southgate KM, Fisher M, Banning AP, Thurston VJ, Baker AH, Fabunmi RP, Groves PH, Davies M, Newby AC. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res. 1996; 79: 1177–1187.[Abstract/Free Full Text]
44. Southgate KM, Davies M, Booth RF, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J. 1992; 288 (Pt 1): 93–99.
45. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol. 1996; 16: 28–33.[Abstract/Free Full Text]
46. Cai WJ, Koltai S, Kocsis E, Scholz D, Kostin S, Luo X, Schaper W, Schaper J. Remodeling of the adventitia during coronary arteriogenesis. Am J Physiol Heart Circ Physiol. 2003; 284: H31–H40.[Abstract/Free Full Text]
47. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol. 1997; 17: 1859–1867.[Free Full Text]
48. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003; 349: 2316–2325.[Abstract/Free Full Text]
49. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A. 1991; 88: 8154–8158.[Abstract/Free Full Text]
50. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994; 94: 2493–2503.[Medline] [Order article via Infotrieve]
51. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–874.[CrossRef][Medline] [Order article via Infotrieve]
52. Hayden MRT, S.C. Arteriogenesis. Angiogenesis within Unstable Atherosclerotic Plaque—Interactions with Extracellular Matrix. Current Interventional Cardiology Reports. 2000; 2: 218–227.
53. Tummalapalli CM, Tyagi SC. Responses of vascular smooth muscle cell to extracellular matrix degradation. J Cell Biochem. 1999; 75: 515–527.[CrossRef][Medline] [Order article via Infotrieve]
54. Barger AC, Beeuwkes R, 3rd, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med. 1984; 310: 175–177.[Medline] [Order article via Infotrieve]
55. Shapiro SD Proteolysis in the lung. Eur Respir J Suppl. 2003; 44: 30s–32s.[CrossRef][Medline] [Order article via Infotrieve]
56. Shapiro SD. Proteinases in chronic obstructive pulmonary disease. Biochem Soc Trans. 2002; 30: 98–102.[CrossRef][Medline] [Order article via Infotrieve]
57. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 1997; 277: 2002–2004.[Abstract/Free Full Text]
58. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax. 2005; 60: 605–609.[Abstract/Free Full Text]
59. Wright JL, Farmer SG, Churg A. A neutrophil elastase inhibitor reduces cigarette smoke-induced remodelling of lung vessels. Eur Respir J. 2003; 22: 77–81.[Abstract/Free Full Text]
60. Radhakrishnamurthy B, Jeansonne NE, Smart FW, Berenson GS. Proteoglycans from lungs of rabbits treated with pronase and cadmium chloride. Am Rev Respir Dis. 1985; 131: 855–861.[Medline] [Order article via Infotrieve]
61. Kirschvink N, Vincke G, Fievez L, Onclinx C, Wirth D, Belleflamme M, Louis R, Cataldo D, Peck MJ, Gustin P. Repeated cadmium nebulizations induce pulmonary MMP-2 and MMP-9 production and emphysema in rats. Toxicology. 2005; 211: 36–48.[CrossRef][Medline] [Order article via Infotrieve]
62. Abu-Hayyeh S, Sian M, Jones KG, Manuel A, Powell JT. Cadmium accumulation in aortas of smokers. Arterioscler Thromb Vasc Biol. 2001; 21: 863–867.[Abstract/Free Full Text]
63. Navas-Acien A, Selvin E, Sharrett AR, Calderon-Aranda E, Silbergeld E, Guallar E. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation. 2004; 109: 3196–3201.[Abstract/Free Full Text]
64. Shah PK. Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. Circulation. 1997; 96: 2115–2117.[Free Full Text]
65. Kim SC, Singh M, Huang J, Prestigiacomo CJ, Winfree CJ, Solomon RA, Connolly ES, Jr. Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery. 1997; 41: 642–666.[CrossRef][Medline] [Order article via Infotrieve]
66. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003; 290: 898–904.[Abstract/Free Full Text]
67. Waters D, Lesperance J, Gladstone P, Boccuzzi SJ, Cook T, Hudgin R, Krip G, Higginson L. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group. Circulation. 1996; 94: 614–621.[Abstract/Free Full Text]
68. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997; 336: 1276–1282.[Abstract/Free Full Text]
69. Himbert D, Klutman M, Steg G, White K, Gulba DC. Cigarette smoking and acute coronary syndromes: a multinational observational study. Int J Cardiol. 2005; 100: 109–117.[CrossRef][Medline] [Order article via Infotrieve]
70. Hsia J, Aragaki A, Bloch M, LaCroix AZ, Wallace R. Predictors of angina pectoris versus myocardial infarction from the Women’s Health Initiative Observational Study. Am J Cardiol. 2004; 93: 673–678.[CrossRef][Medline] [Order article via Infotrieve]
71. Kennon S, Suliman A, MacCallum PK, Ranjadayalan K, Wilkinson P, Timmis AD. Clinical characteristics determining the mode of presentation in patients with acute coronary syndromes. J Am Coll Cardiol. 1998; 32: 2018–2022.[Abstract/Free Full Text]
72. Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation. 1998; 97: 2110–2116.[Abstract/Free Full Text]
73. Chase AJ, Newby AC. Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling. J Vasc Res. 2003; 40: 329–343.[CrossRef][Medline] [Order article via Infotrieve]
74. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation. 1995; 92: 1084–1088.[Abstract/Free Full Text]
75. Lindstedt KA, Kovanen PT. Mast cells in vulnerable coronary plaques: potential mechanisms linking mast cell activation to plaque erosion and rupture. Curr Opin Lipidol. 2004; 15: 567–573.[CrossRef][Medline] [Order article via Infotrieve]
76. Kelley J, Hemontolor G, Younis W, Li C, Krishnaswamy G, Chi DS. Mast cell activation by lipoproteins. Methods Mol Biol. 2005; 315: 341–348.
77. Suzuki Y, Yoshimaru T, Inoue T, Niide O, Ra C. Role of oxidants in mast cell activation. Chem Immunol Allergy. 2005; 87: 32–42.[Medline] [Order article via Infotrieve]
78. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995; 92: 3893–3897.[Abstract/Free Full Text]
79. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol. 1995; 154: 4379–4389.[Abstract]
80. Yakubenko VP, Lobb RR, Plow EF, Ugarova TP. Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon alpha(4)beta(1)-mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin. Exp Cell Res. 2000; 260: 73–84.[CrossRef][Medline] [Order article via Infotrieve]
81. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685–1695.[Free Full Text]
82. Amorino GP, Hoover RL. Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am J Pathol. 1998; 152: 199–207.[Abstract]
83. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, Amento E, Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994; 75: 181–189.[Abstract/Free Full Text]
84. Ryder MI, Saghizadeh M, Ding Y, Nguyen N, Soskolne A. Effects of tobacco smoke on the secretion of interleukin-1beta, tumor necrosis factor-alpha, and transforming growth factor-beta from peripheral blood mononuclear cells. Oral Microbiol Immunol. 2002; 17: 331–336.[CrossRef][Medline] [Order article via Infotrieve]
85. Cucina A, Sapienza P, Corvino V, Borrelli V, Randone B, Santoro-D’Angelo L, Cavallaro A. Nicotine induces platelet-derived growth factor release and cytoskeletal alteration in aortic smooth muscle cells. Surgery. 2000; 127: 72–78.[CrossRef][Medline] [Order article via Infotrieve]
86. Carty CS, Soloway PD, Kayastha S, Bauer J, Marsan B, Ricotta JJ, Dryjski M Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells. J Vasc Surg. 1996; 24: 927–934.[CrossRef][Medline] [Order article via Infotrieve]
87. Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J. 1993; 296 (Pt 3): 803–809.
88. Hojo Y, Ikeda U, Takahashi M, Sakata Y, Takizawa T, Okada K, Saito T, Shimada K. Matrix metalloproteinase-1 expression by interaction between monocytes and vascular endothelial cells. J Mol Cell Cardiol. 2000; 32: 1459–1468.[CrossRef][Medline] [Order article via Infotrieve]
89. Kalra VK, Ying Y, Deemer K, Natarajan R, Nadler JL, Coates TD. Mechanism of cigarette smoke condensate induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol. 1994; 160: 154–162.[CrossRef][Medline] [Order article via Infotrieve]
90. Lin R, Liu J, Gan W, Yang G. C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Biol Pharm Bull. 2004; 27: 1537–1543.[CrossRef][Medline] [Order article via Infotrieve]
91. Harding SA, Sarma J, Josephs DH, Cruden NL, Din JN, Twomey PJ, Fox KA, Newby DE. Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation. 2004; 109: 1926–1929.[Abstract/Free Full Text]
92. Galis ZS, Asanuma K, Godin D, Meng X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation. 1998; 97: 2445–2453.[Abstract/Free Full Text]
93. Chen HH, Wang DL. Nitric oxide inhibits matrix metalloproteinase-2 expression via the induction of activating transcription factor 3 in endothelial cells. Mol Pharmacol. 2004; 65: 1130–1140.[Abstract/Free Full Text]
94. Eberhardt W, Huwiler A, Beck KF, Walpen S, Pfeilschifter J. Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. J Immunol. 2000; 165: 5788–5797.[Abstract/Free Full Text]
95. Parodi FE, Mao D, Ennis TL, Bartoli MA, Thompson RW. Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-kappaB. J Vasc Surg. 2005; 41: 479–489.[CrossRef][Medline] [Order article via Infotrieve]
96. Walters MJ, Paul-Clark MJ, McMaster SK, Ito K, Adcock IM, Mitchell JA Cigarette smoke activates human monocytes by an oxidant AP-1 signalling pathway: implications for steroid resistance. Mol Pharmacol. 2005; 68: 1343–1353.[Abstract/Free Full Text]
97. Wang XD, Liu C, Bronson RT, Smith DE, Krinsky NI, Russell M. Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke. J Natl Cancer Inst. 1999; 91: 60–66.[Abstract/Free Full Text]
98. Chase AJ, Bond M, Crook MF, Newby AC. Role of nuclear factor-kappa B activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol. 2002; 22: 765–771.[Abstract/Free Full Text]
99. Bond M, Chase AJ, Baker AH, Newby AC. Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res. 2001; 50: 556–565.[Abstract/Free Full Text]
100. Mochida-Nishimura K, Surewicz K, Cross JV, Hejal R, Templeton D, Rich EA, Toossi Z. Differential activation of MAP kinase signaling pathways and nuclear factor-kappaB in bronchoalveolar cells of smokers and nonsmokers. Mol Med. 2001; 7: 177–185.[Medline] [Order article via Infotrieve]
101. Lindholt JS, Jorgensen B, Shi GP, Henneberg EW. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2003; 25: 546–551.[CrossRef][Medline] [Order article via Infotrieve]
102. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 1996; 98: 2572–2579.[Medline] [Order article via Infotrieve]
103. Phillips PG, Birnby LM. Nitric oxide modulates caveolin-1 and matrix metalloproteinase-9 expression and distribution at the endothelial cell/tumor cell interface. Am J Physiol Lung Cell Mol Physiol. 2004; 286: L1055–L1065.[Abstract/Free